Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06486558 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of HU6
A Phase 1 study, sponsored by Rivus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT06486558 is a Phase 1 study that has completed, run by Rivus Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT06486558, a Phase 1 study, has completed, sponsored by Rivus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a 2-part study. Part 1 will assess the relative bioavailability of the new 450 mg tablet test formulation compared to the 150 mg capsule reference formulation (3 x 150 mg). Part 1 dosing will be conducted in the fasted state. Part 2 will assess the effect of food (and fat content) on the pharmacokinetics of the 450 mg tablet test formulation.
Interventions
- DRUG HU6 450 mg Tablet
- DRUG HU6 150 mg Capsules x 3 (Total dose = 450 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2024-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06486558
The ClinicalTrials.gov registry entry for NCT06486558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rivus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HU6 450 mg Tablet is the first listed.
NCT06486558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06486558 about?
NCT06486558 is a clinical study titled "Relative Bioavailability Study of HU6". This is a 2-part study. Part 1 will assess the relative bioavailability of the new 450 mg tablet test formulation compared to the 150 mg capsule reference formulation (3 x 150 mg). Part 1 dosing will be conducted in the fasted state. Part 2 will assess the effect of food (and fat content) on the pha...
What is the current status of trial NCT06486558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2024-07-24. Estimated completion is 2024-12-15.
What interventions are being tested in trial NCT06486558?
The interventions under investigation include: HU6 450 mg Tablet (DRUG), HU6 150 mg Capsules x 3 (Total dose = 450 mg) (DRUG).
Who is sponsoring clinical trial NCT06486558?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.